SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript
SANUWAVE (SNWV) reported Q2 2026 revenue of $9.7M, down 3% from $10.1M, driven by lower capital equipment sales. UltraMIST applicator revenue rose 13% to $7.3M, while UltraMIST system revenue fell 34% to $2.3M. The company posted a $0.7M net loss and withdrew FY2026 guidance amid proposed 2027 Medicare reimbursement cuts.
How this was made
The 30-second read
Why it matters
The company withdrew full-year 2026 guidance and warned that a proposed 2027 Physician Fee Schedule rule could reduce UltraMIST reimbursement from an average ~$397 to about ~$316, with further reductions possible in 2028. This regulatory uncertainty, combined with Q2 operating and net losses and gross margin compression, is likely to drive near-term repricing and heightened volatility.
Market read
Traders get a concrete reimbursement downside scenario, a guidance withdrawal, and segment-level performance (applicators up, systems down) that can inform positioning ahead of CMS final determinations.
What to watch
Management cites CMS nomination of code 97610 as a mispriced code with a formal response during a 60-day comment period ending Sept. 14, which could mitigate the magnitude/timing of reimbursement cuts.
Background
SANUWAVE sells UltraMIST therapy via applicators and systems; its economics are sensitive to Medicare reimbursement for code 97610 and related skin substitute reimbursement changes affecting wound care practitioners.
Ticker impact
SANUWAVE reported Q2 revenue of $9.7M (down 3%) and withdrew FY2026 guidance due to pending final Medicare reimbursement determinations.
Likely downside bias and higher volatility until final Physician Fee Schedule and HOPD reimbursement levels are confirmed.
The call discloses both financial results (losses, margin compression) and a concrete regulatory scenario (97610 average dropping from ~$397 to ~$316 in 2027) alongside a full-year guidance withdrawal.
Market effects
Highlights reimbursement-driven stress in wound care and the risk of cannibalization from secondary markets for medical devices.
No clear regional-specific impact beyond US Medicare reimbursement mechanics.
Primarily US reimbursement policy; limited direct global read-through.
Counterpoint
UltraMIST applicator revenue grew 13% and unit volume rose 27% YoY, suggesting demand for consumables may partially offset system weakness if reimbursement stabilizes.
Key entities
- companySANUWAVE
UltraMIST wound care therapy provider reporting Q2 results, margin compression, and guidance withdrawal tied to Medicare reimbursement uncertainty.
- regulatorCMS
Centers for Medicare & Medicaid Services, referenced for proposed Physician Fee Schedule changes and nomination of code 97610 as mispriced.
- reimbursement_codeUltraMIST 97610
Medicare billing code for UltraMIST reimbursement, cited as potentially dropping in 2027 under the proposed Physician Fee Schedule rule.
